Sufentanil ameliorates oxygen‑glucose deprivation/reoxygenation‑induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway

Wang,Lianggang; Ge,Chunlin; Zhang,Xinxin

doi:10.3892/etm.2022.11364

Sufentanil ameliorates oxygen‑glucose deprivation/reoxygenation‑induced endothelial barrier dysfunction in HCMECs via the PI3K/Akt signaling pathway

Authors:
- Lianggang Wang
- Chunlin Ge
- Xinxin Zhang
View Affiliations

Affiliations: Department of Anesthesiology, Shanghai Xuhui Central Hospital, Shanghai 200031, P.R. China
Published online on: May 11, 2022 https://doi.org/10.3892/etm.2022.11364
Article Number: 437
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ischemic heart disease, a chronic myocardial damage disease caused by coronary artery ischemia, is the leading cause of death worldwide. The aim of the present study was to explore the efficacy of sufentanil in myocardial ischemia/reperfusion (I/R) injury. Oxygen and glucose deprivation/reoxygenation (OGD/R) was utilized to induce human cardiac microvascular endothelial cells (HCMECs) to simulate myocardial I/R injury in vitro. The Cell Counting Kit‑8 assay was used to detect the effects of sufentanil on HCMECs and OGD/R‑induced HCMECs. The TUNEL, lactate dehydrogenase (LDH) activity, immunofluorescence and in vitro permeability assays, were used to assess apoptosis, LDH activity, VE‑cadherin protein expression levels and endothelial barrier function in OGD/R‑induced HCMECs, respectively. Moreover, western blotting was performed to assess the protein expression levels of apoptosis, endothelial barrier function and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt)‑related proteins. The results demonstrated that sufentanil had no significant influence on the viability of HCMECs but increased the viability of OGD/R‑induced HCMECs in a dose‑dependent manner. Furthermore, sufentanil inhibited cell apoptosis and permeability of OGD/R‑induced HCMECs but enhanced the protein expression levels of tight junction proteins, including ZO‑1, Occludin, VE‑cadherin and Claudin‑5. Sufentanil was also demonstrated to activate the PI3K/Akt signaling pathway. In addition, the use of LY294002, an inhibitor of the PI3K/Akt signaling pathway, partially abolished the protective effects of sufentanil on apoptosis, permeability and tight junction protein expression levels. These results indicated that sufentanil ameliorated OGD/R‑induced endothelial barrier dysfunction in HCMECs, potentially via the PI3K/Akt signaling pathway. The present study therefore suggested that sufentanil may serve as a novel therapeutic option for the improvement of myocardial I/R injury.

View Figures

View References

1	Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F and Lopez-Jimenez F: Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies. Lancet. 368:666–678. 2006.PubMed/NCBI View Article : Google Scholar
2	Wang N, Song G, Yang Y, Yuan W and Qi M: Inactivated Lactobacillus promotes protection against myocardial ischemia-reperfusion injury through NF-κB pathway. Biosci Rep. 37(BSR20171025)2017.PubMed/NCBI View Article : Google Scholar
3	Wang J, Toan S and Zhou H: New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis. 23:299–314. 2020.PubMed/NCBI View Article : Google Scholar
4	Gao XM, Su Y, Moore S, Han LP, Kiriazis H, Lu Q, Zhao WB, Ruze A, Fang BB, Duan MJ and Du XJ: Relaxin mitigates microvascular damage and inflammation following cardiac ischemia-reperfusion. Basic Res Cardiol. 114(30)2019.PubMed/NCBI View Article : Google Scholar
5	Beckman JS, Beckman TW, Chen J, Marshall PA and Freeman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 87:1620–1624. 1990.PubMed/NCBI View Article : Google Scholar
6	Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ, Thompson CI, Kaley G, Wolin MS and Hintze TH: Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res. 84:840–845. 1999.PubMed/NCBI View Article : Google Scholar
7	Radomski MW, Palmer RM and Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1057–1058. 1987.PubMed/NCBI View Article : Google Scholar
8	Reardon CE, Kane-Gill SL, Smithburger PL and Dasta JF: Sufentanil sublingual tablet: A new option for acute pain management. Ann Pharmacother. 53:1220–1226. 2019.PubMed/NCBI View Article : Google Scholar
9	Kim DK, Yoon SH, Kim JY, Oh CH, Jung JK and Kim J: Comparison of the effects of sufentanil and fentanyl intravenous patient controlled analgesia after lumbar fusion. J Korean Neurosurg Soc. 60:54–59. 2017.PubMed/NCBI View Article : Google Scholar
10	Ohnesorge H, Alpes A, Baron R and Gierthmühlen J: Influence of intraoperative remifentanil and sufentanil on sensory perception: A randomized trial. Curr Med Res Opin. 32:1797–1805. 2016.PubMed/NCBI View Article : Google Scholar
11	Yang Y, Teng X and Zhu J: Sufentanil blunts the myocardial stress induced by tracheal intubation in older adult patients with coronary heart disease better than equipotent fentanyl. Ann Palliat Med. 9:3909–3914. 2020.PubMed/NCBI View Article : Google Scholar
12	Lemoine S, Zhu L, Massetti M, Gérard JL and Hanouz JL: Continuous administration of remifentanil and sufentanil induces cardioprotection in human myocardium, in vitro. Acta Anaesthesiol Scand. 55:758–764. 2011.PubMed/NCBI View Article : Google Scholar
13	Liu X, Jing G, Bai J and Yuan H: Effect of sufentanil preconditioning on myocardial P-Akt expression in rats during myocardial ischemia-reperfusion. Nan Fang Yi Ke Da Xue Xue Bao. 34:335–340. 2014.PubMed/NCBI(In Chinese).
14	Wei J, Gou Z, Wen Y, Luo Q and Huang Z: Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy. Biomed Pharmacother. 129(110484)2020.PubMed/NCBI View Article : Google Scholar
15	Li Y, Xia J, Jiang N, Xian Y, Ju H, Wei Y and Zhang X: Corin protects H₂O₂-induced apoptosis through PI3K/AKT and NF-κB pathway in cardiomyocytes. Biomed Pharmacother. 97:594–599. 2018.PubMed/NCBI View Article : Google Scholar
16	Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell. 170:605–635. 2017.PubMed/NCBI View Article : Google Scholar
17	Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8:179–183. 2005.PubMed/NCBI View Article : Google Scholar
18	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002.PubMed/NCBI View Article : Google Scholar
19	Chen E, Chen C, Niu Z, Gan L, Wang Q, Li M, Cai X, Gao R, Katakam S, Chen H, et al: Poly(I:C) preconditioning protects the heart against myocardial ischemia/reperfusion injury through TLR3/PI3K/Akt-dependent pathway. Signal Transduct Target Ther. 5(216)2020.PubMed/NCBI View Article : Google Scholar
20	Jacob B, Kloss N, Böhle S, Kirschberg J, Zippelius T, Heinecke M, Matziolis G and Röhner E: Tranexamic acid is toxic on human chondrocytes, in vitro. J Orthop. 20:1–5. 2019.PubMed/NCBI View Article : Google Scholar
21	Qi K, Yang Y, Geng Y, Cui H, Li X, Jin C, Chen G, Tian X and Meng X: Tongxinluo attenuates oxygen-glucose-serum deprivation/restoration-induced endothelial barrier breakdown via peroxisome proliferator activated receptor-_α/angiopoietin-like 4 pathway in high glucose-incubated human cardiac microvascular endothelial cells. Medicine (Baltimore). 99(e21821)2020.PubMed/NCBI View Article : Google Scholar
22	Chen QL, Gu EW, Zhang L, Cao YY, Zhu Y and Fang WP: Diabetes mellitus abrogates the cardioprotection of sufentanil against ischaemia/reperfusion injury by altering glycogen synthase kinase-3_β. Acta Anaesthesiol Scand. 57:236–242. 2013.PubMed/NCBI View Article : Google Scholar
23	Tao H, Nuo M and Min S: Sufentanil protects the rat myocardium against ischemia-reperfusion injury via activation of the ERK1/2 pathway. Cytotechnology. 70:169–176. 2018.PubMed/NCBI View Article : Google Scholar
24	Wu Y, Gu EW, Zhu Y, Zhang L, Liu XQ and Fang WP: Sufentanil limits the myocardial infarct size by preservation of the phosphorylated connexin 43. Int Immunopharmacol. 13:341–346. 2012.PubMed/NCBI View Article : Google Scholar
25	Yu H, Kalogeris T and Korthuis RJ: Reactive species-induced microvascular dysfunction in ischemia/reperfusion. Free Radic Biol Med. 135:182–197. 2019.PubMed/NCBI View Article : Google Scholar
26	Müller-Werdan U, Prondzinsky R and Werdan K: Effect of inflammatory mediators on cardiovascular function. Curr Opin Crit Care. 22:453–463. 2016.PubMed/NCBI View Article : Google Scholar
27	Ito H: Etiology and clinical implications of microvascular dysfunction in patients with acute myocardial infarction. Int Heart J. 55:185–189. 2014.PubMed/NCBI View Article : Google Scholar
28	Ríos-Navarro C, Hueso L, Miñana G, Núñez J, Ruiz-Saurí A, Sanz MJ, Cànoves J, Chorro FJ, Piqueras L and Bodí V: Coronary serum obtained after myocardial infarction induces angiogenesis and microvascular obstruction repair. Role of hypoxia-inducible factor-1A. Rev Esp Cardiol (Engl Ed). 71:440–449. 2018.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).
29	Zhu T, Yao Q, Wang W, Yao H and Chao J: iNOS induces vascular endothelial cell migration and apoptosis via autophagy in ischemia/reperfusion injury. Cell Physiol Biochem. 38:1575–1588. 2016.PubMed/NCBI View Article : Google Scholar
30	Filep JG, Sirois MG, Foldes-Filep E, Rousseau A, Plante GE, Fournier A, Yano M and Sirois P: Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol. 109:880–886. 1993.PubMed/NCBI View Article : Google Scholar
31	Tornavaca O, Chia M, Dufton N, Almagro LO, Conway DE, Randi AM, Schwartz MA, Matter K and Balda MS: ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J Cell Biol. 208:821–838. 2015.PubMed/NCBI View Article : Google Scholar
32	Giannotta M, Trani M and Dejana E: VE-cadherin and endothelial adherens junctions: Active guardians of vascular integrity. Dev Cell. 26:441–454. 2013.PubMed/NCBI View Article : Google Scholar
33	Xie L, Wu Y, Fan Z, Liu Y and Zeng J: Astragalus polysaccharide protects human cardiac microvascular endothelial cells from hypoxia/reoxygenation injury: The role of PI3K/AKT, Bax/Bcl-2 and caspase-3. Mol Med Rep. 14:904–910. 2016.PubMed/NCBI View Article : Google Scholar
34	Xing X, Guo S, Zhang G, Liu Y, Bi S, Wang X and Lu Q: miR-26a-5p protects against myocardial ischemia/reperfusion injury by regulating the PTEN/PI3K/AKT signaling pathway. Braz J Med Biol Res. 53(e9106)2020.PubMed/NCBI View Article : Google Scholar
35	Yu P, Ma S, Dai X and Cao F: Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signaling. Am J Transl Res. 12:4467–4477. 2020.PubMed/NCBI
36	Wu QL, Shen T, Ma H and Wang JK: Sufentanil postconditioning protects the myocardium from ischemia-reperfusion via PI3K/Akt-GSK-3_β pathway. J Surg Res. 178:563–570. 2012.PubMed/NCBI View Article : Google Scholar